The company said U.S. dialysis treatments for Q1 2025 decreased compared to Q1 2024, driven by a decrease in treatment days as well as decreased average treatments per 1 day related to increased missed treatments impacted by storms and the seasonal flu as well as increased mortality related to a more severe flu season.

10-QQuarterly reportFiled May 12, 2025Period of report Mar 31, 2025Summary published (UTC) Oct 11, 2026

Key points

AI summary

The company said U.S. dialysis treatments for Q1 2025 decreased compared to Q1 2024, driven by a decrease in treatment days as well as decreased average treatments per 1 day related to increased missed treatments impacted by storms and the seasonal flu as well as increased mortality related to a more severe flu season.
The company said phosphate binders were incorporated into the ESRD PPS bundled payment on January 1, 2025, and during the TDAPA period Medicare payment for phosphate binders is based on average sales price increased by a fixed monthly amount of $36.41. DaVita cited increases in pharmaceutical costs principally due to the administration of phosphate binders as a driver of increased patient care costs per treatment.
DaVita said net cash provided by operating activities for Q1 2025 increased compared to the prior year period. The company said it had net debt issuances of $425 million and used cash for repayment of $93 million in interest-free funding from UnitedHealth Group and repurchase of 3.7 million shares.
As of March 31, 2025, DaVita IKC provided integrated care and disease management services to approximately 62,100 patients in risk-based integrated care arrangements and to an additional 9,300 patients in other integrated care arrangements, the company said. Its international dialysis operations provided dialysis and administrative services through a total of 512 outpatient dialysis centers located in 13 countries outside the United States.

Key figures

Quarter ended March 31, 2025

Revenue: $3.2B
Operating income: $439M
Net income: $163M
EPS: $2.00
Operating cash flow: $180M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

U.S. dialysis treatment volume decline

The company said U.S. dialysis treatments for Q1 2025 decreased compared to Q1 2024, driven by a decrease in treatment days as well as decreased average treatments per 1 day related to increased missed treatments impacted by storms and the seasonal flu as well as increased mortality related to a more severe flu season.

Source · Based on the MD&A text of the filing

Phosphate binders incorporated into ESRD PPS bundled payment

The company said phosphate binders were incorporated into the ESRD PPS bundled payment on January 1, 2025, and during the TDAPA period Medicare payment for phosphate binders is based on average sales price increased by a fixed monthly amount of $36.41. DaVita cited increases in pharmaceutical costs principally due to the administration of phosphate binders as a driver of increased patient care costs per treatment.

Source · Based on the MD&A text of the filing

Operating cash flow and use of funds

DaVita said net cash provided by operating activities for Q1 2025 increased compared to the prior year period. The company said it had net debt issuances of $425 million and used cash for repayment of $93 million in interest-free funding from UnitedHealth Group and repurchase of 3.7 million shares.

Source · Based on the MD&A text of the filing

IKC patient count and international dialysis centers

As of March 31, 2025, DaVita IKC provided integrated care and disease management services to approximately 62,100 patients in risk-based integrated care arrangements and to an additional 9,300 patients in other integrated care arrangements, the company said. Its international dialysis operations provided dialysis and administrative services through a total of 512 outpatient dialysis centers located in 13 countries outside the United States.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.